Disproportionality Analysis of Anaphylactic Reactions after Vaccination with mRNA COVID-19 Vaccines in the United States

One year after the emergence of the novel coronavirus SARS-CoV-2 that causes the coronavirus disease 2019 (COVID-19), the United States Food and Drug Administration (FDA) granted two Emergency Use Authorizations (EUA) for two novel mRNA COVID-19 vaccines. Reports of acute hypersensitivity reactions in the real world after EUA are creating anxiety among potential vaccine recipients and may delay achieving universal vaccination (1). Although the Centers for Disease Control and Prevention (CDC) and the FDA jointly monitor vaccine adverse reactions through a variety of surveillance systems such as the Vaccine Adverse Event Reporting System (VAERS) or the CDC's Vaccine Safety Datalink (2), local health care professionals also play an essential role in monitoring vaccine safety, reporting to VAERS, and providing factual and up-to-date information to increase vaccine acceptance.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letter Source Type: research